Immunotherapy in Soft Tissue and Bone Sarcoma: Unraveling the Barriers to Effectiveness

Overview

Journal Theranostics

Date 2022 Sep 28

PMID 36168619

Authors

Myrofora Panagi

Pampina Pilavaki

Anastasia Constantinidou

Triantafyllos Stylianopoulos

Affiliations

Soon will be listed here.

Abstract

Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the human lifespan, at any part of the body. Surgery remains the optimal treatment modality whilst response to conventional treatments, such as chemotherapy and radiation, is minimal. Immunotherapy has emerged as a novel approach to treat different cancer types but efficacy in soft tissue sarcoma and bone sarcoma is limited to distinct subtypes. Growing evidence shows that cancer-stroma cell interactions and their microenvironment play a key role in the effectiveness of immunotherapy. However, the pathophysiological and immunological properties of the sarcoma tumor microenvironment in relation to immunotherapy advances, has not been broadly reviewed. Here, we provide an up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma, identify barriers posed by the sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers.

Citing Articles

Targeting cancer stem cells by TPA leads to inhibition of refractory sarcoma and extended overall survival.

Galoian K, Bilbao D, Denny C, Gallego N, Roberts E, Martinez D Mol Ther Oncol. 2024; 32(4):200905.

PMID: 39640862 PMC: 11617462. DOI: 10.1016/j.omton.2024.200905.

A unique presentation of pericardial epithelioid angiosarcoma with multifaceted complications.

Al Sakan M, Chihab M, Alkhateb O, Fakhreddine O, Tfayli A Ann Med Surg (Lond). 2024; 86(10):6266-6271.

PMID: 39359772 PMC: 11444636. DOI: 10.1097/MS9.0000000000002521.

The application of lung immune prognostic index in predicting the prognosis of 302 STS patients.

Jiang Y, Zou C, He X, Li L, Luo Y, Lu M Front Oncol. 2024; 14:1460600.

PMID: 39314631 PMC: 11417100. DOI: 10.3389/fonc.2024.1460600.

A Review on Canine and Human Soft Tissue Sarcomas: New Insights on Prognosis Factors and Treatment Measures.

DellAnno F, Giugliano R, Listorti V, Razzuoli E Vet Sci. 2024; 11(8).

PMID: 39195816 PMC: 11358912. DOI: 10.3390/vetsci11080362.

Current advance of nanotechnology in diagnosis and treatment for malignant tumors.

Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y Signal Transduct Target Ther. 2024; 9(1):200.

PMID: 39128942 PMC: 11323968. DOI: 10.1038/s41392-024-01889-y.

References

Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T . Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget. 2017; 8(15):24506-24517. PMC: 5421866. DOI: 10.18632/oncotarget.15534. View

Jones R, Ravi V, Brohl A, Chawla S, Ganjoo K, Italiano A . Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022; 8(5):740-747. PMC: 8972152. DOI: 10.1001/jamaoncol.2021.3547. View

Chen L, Taylor J, Sabins N, Lowe D, Qu Y, You Z . Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther. 2013; 20(8):469-77. PMC: 3775601. DOI: 10.1038/cgt.2013.42. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Klose C, Berchtold S, Schmidt M, Beil J, Smirnow I, Venturelli S . Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy. BMC Cancer. 2019; 19(1):1172. PMC: 6889644. DOI: 10.1186/s12885-019-6387-5. View

Sheridan C . Pancreatic cancer provides testbed for first mechanotherapeutics. Nat Biotechnol. 2019; 37(8):829-831. DOI: 10.1038/d41587-019-00019-2. View

Dumars C, Ngyuen J, Gaultier A, Lanel R, Corradini N, Gouin F . Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 2016; 7(48):78343-78354. PMC: 5346643. DOI: 10.18632/oncotarget.13055. View

Zhao H, Zhao X, Du P, Qi G . Construction of random tumor transcriptome expression library for creating and selecting novel tumor antigens. Tumour Biol. 2016; 37(9):12877-12887. DOI: 10.1007/s13277-016-5201-0. View

10.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

11.

Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U . Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Pediatr Blood Cancer. 2017; 65(1). DOI: 10.1002/pbc.26719. View

12.

Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H . Anti-TGF-β antibody combined with dendritic cells produce antitumor effects in osteosarcoma. Clin Orthop Relat Res. 2012; 470(8):2288-94. PMC: 3392369. DOI: 10.1007/s11999-012-2299-2. View

13.

Pillozzi S, Bernini A, Palchetti I, Crociani O, Antonuzzo L, Campanacci D . Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers (Basel). 2021; 13(12). PMC: 8233868. DOI: 10.3390/cancers13123044. View

14.

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

15.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

16.

Hess C, Neri D . The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity. Cancer Immunol Immunother. 2015; 64(5):635-44. PMC: 11029586. DOI: 10.1007/s00262-015-1666-8. View

17.

Bulgarelli J, Tazzari M, Granato A, Ridolfi L, Maiocchi S, De Rosa F . Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors. Front Immunol. 2019; 10:2353. PMC: 6794451. DOI: 10.3389/fimmu.2019.02353. View

18.

Arab S, Motamedi M, Hadjati J . Effects of Dendritic Cell Vaccine Activated with Components of Lieshmania Major on Tumor Specific Response. Iran J Immunol. 2019; 16(4):268-277. DOI: 10.22034/IJI.2019.80278. View

19.

Nakashima H, Terabe M, Berzofsky J, Husain S, Puri R . A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models. J Immunol. 2011; 187(10):4935-46. PMC: 3730529. DOI: 10.4049/jimmunol.1102095. View

20.

Li Q, Hao Z, Hong Y, He W, Zhao W . Reprogramming Tumor Associated Macrophage Phenotype by a Polysaccharide from for Sarcoma Immunotherapy. Int J Mol Sci. 2018; 19(12). PMC: 6320939. DOI: 10.3390/ijms19123816. View